Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19

The ongoing COVID-19 pandemic has infected nearly 3,582,233 individuals with 248,558 deaths since it was first identified in human populations in December 2019 in Wuhan, China. No antiviral therapies or vaccines are available for their treatment or prevention. Passive immunization PI through broadly...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzoughool, Foad, Alanagreh, Lo’ai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Article Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306893/
https://www.ncbi.nlm.nih.gov/pubmed/32310190
http://dx.doi.org/10.3233/JRS-201017
_version_ 1783548738678030336
author Alzoughool, Foad
Alanagreh, Lo’ai
author_facet Alzoughool, Foad
Alanagreh, Lo’ai
author_sort Alzoughool, Foad
collection PubMed
description The ongoing COVID-19 pandemic has infected nearly 3,582,233 individuals with 248,558 deaths since it was first identified in human populations in December 2019 in Wuhan, China. No antiviral therapies or vaccines are available for their treatment or prevention. Passive immunization PI through broadly neutralizing antibodies that bind to the specific antigens of SARS-CoV 2 might be a potential solution to address the immediate health threat of COVID-19 pandemic while vaccines are being developed. The PI approach in treating COVID-19 is discussed herein, including a summary of its historical applications to confront epidemics.
format Online
Article
Text
id pubmed-7306893
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-73068932020-06-23 Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19 Alzoughool, Foad Alanagreh, Lo’ai Int J Risk Saf Med Article Commentary The ongoing COVID-19 pandemic has infected nearly 3,582,233 individuals with 248,558 deaths since it was first identified in human populations in December 2019 in Wuhan, China. No antiviral therapies or vaccines are available for their treatment or prevention. Passive immunization PI through broadly neutralizing antibodies that bind to the specific antigens of SARS-CoV 2 might be a potential solution to address the immediate health threat of COVID-19 pandemic while vaccines are being developed. The PI approach in treating COVID-19 is discussed herein, including a summary of its historical applications to confront epidemics. IOS Press 2020-05-19 /pmc/articles/PMC7306893/ /pubmed/32310190 http://dx.doi.org/10.3233/JRS-201017 Text en © 2020 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article Commentary
Alzoughool, Foad
Alanagreh, Lo’ai
Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
title Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
title_full Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
title_fullStr Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
title_full_unstemmed Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
title_short Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
title_sort coronavirus drugs: using plasma from recovered patients as a treatment for covid-19
topic Article Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306893/
https://www.ncbi.nlm.nih.gov/pubmed/32310190
http://dx.doi.org/10.3233/JRS-201017
work_keys_str_mv AT alzoughoolfoad coronavirusdrugsusingplasmafromrecoveredpatientsasatreatmentforcovid19
AT alanagrehloai coronavirusdrugsusingplasmafromrecoveredpatientsasatreatmentforcovid19

Ejemplares similares